drugset / Trial / NCT06563856
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
Non-randomizedSequentialOpen-labelBasic science
Summary
The primary objective of this study is to assess the pharmacokinetics (PK) parameters of a single subcutaneous (SubQ) infusion of TEPEZZA with and without ENHANZE™ Drug Product (EDP) at 2 dose levels in healthy adult participants.
Timeline
- Start
- 2020-09-22
- Primary completion
- 2021-05-27
- Completion
- 2021-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EDP | Unknown | — | Subcutaneous |
| Subject | Teprotumumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.